Evidence map›Paper›PMID 41736049›Full record

ArticleTrials2026

Efficacy and safety of the Exfoliate-Dissolve-Repair skin care approach in the treatment of keratosis pilaris: a randomized controlled clinical trial study protocol.

Yi-Jie Du, Lu Cheng, Feng-Wei Qi, Jie Yang, Hong Meng

Abstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yi-Jie DuSchool of Light Industry Science and Engineering, Beijing Technology & Business University, Beijing, China.
Lu ChengShandong Huawutang Biotechnology Co., Ltd, Jinan, Shandong, China.
Feng-Wei QiShandong Huawutang Biotechnology Co., Ltd, Jinan, Shandong, China.
Jie YangShandong Huawutang Biotechnology Co., Ltd, Jinan, Shandong, China.
Hong MengSchool of Light Industry Science and Engineering, Beijing Technology & Business University, Beijing, China. menghong2000@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKeratosis pilaris (KP) is a chronic skin disease characterized by keratinized hair follicle papules, typically occurring on the arms, thighs, and buttocks. At present, the external treatment plan for KP is relatively singular. To optimize the existing clinical external drug treatment plan for KP, improve side effects, and enhance patients' quality of life, we propose the Exfoliate-Dissolve-Repair (EDR) comprehensive skin care method. Based on the EDR concept, we have designed a treatment plan that combines body scrub and moisturizing lotion. This research plan aims to evaluate the safety and efficacy of a novel skincare combination therapy for KP through a randomized controlled trial.

methodsThis study is a single center, randomized, controlled clinical trial targeting cases of KP aged 18-35 years. Participants (n = 72) were randomly assigned to a treatment group and a control group. The treatment group received EDR comprehensive skin care intervention, while the control group received 0.1% retinoic acid cream intervention. The trial includes a 4-week treatment period, with indicator testing and data collection conducted at 7, 14, 21, and 28 days after the start of treatment. The main outcome measures include the improvement index of follicular papules and evaluation of skin keratinization degree. Secondary outcome measures include skin moisture content, transdermal moisture loss test, skin elasticity, etc. Use the skin lesion condition, blood pressure, heart rate, heart rhythm, and respiratory rate of the subjects as safety evaluation indicators. Exploratory evaluation of the effectiveness and safety of the EDR comprehensive skin care method for KP. DISCUSSION: This study will be the RCT to directly compare the effects of EDR comprehensive skincare approach and 0.1% retinoic acid cream in KP. Findings from the study will provide evidence to inform the clinical management of KP.

trial registrationThis protocol has been registered prospectively in ISRCTN under the ISRCTN14455606 on April 6, 2025.

Indexed as

Abnormalities, MultipleDarier DiseaseEyebrowsSkin CareSkin CreamTretinoinAdolescentAdultFemaleHumansMaleQuality of LifeRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeYoung AdultTretinoinEfficacy and safetyExfoliate-Dissolve-RepairKeratosis pilarisProtocolRCT

Identifiers

PMID41736049
PMCPMC13037331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.